GLPwatch

Exendin-4 decreases amphetamine-induced locomotor activity.

Physiol Behav · 2012

Last updated 2026-05-28

In a study on rats, a single dose of the GLP-1 drug exendin-4 (Ex-4) reduced both normal movement and movement caused by amphetamine, a stimulant drug. The drug did not cause signs of anxiety or discomfort in the rats. The findings suggest GLP-1 signaling may influence behaviors linked to stimulant use.

AI summary of the abstract below.

JournalPhysiol Behav, 2012
Citations81
Relative citation ratio2.64
NIH percentile81
Molecules

Abstract

Glucagon-like peptide-1 (GLP-1) is released in response to nutrient ingestion and is a regulator of energy metabolism and consummatory behaviors through both peripheral and central mechanisms. The GLP-1 receptor (GLP-1R) is widely distributed in the central nervous system, however little is known about how GLP-1Rs regulate ambulatory behavior. The abused psychostimulant amphetamine (AMPH) promotes behavioral locomotor activity primarily by inducing the release of the neurotransmitter dopamine. Here, we identify the GLP-1R agonist exendin-4 (Ex-4) as a modulator of behavioral activation by AMPH. We report that in rats a single acute administration of Ex-4 decreases both basal locomotor activity as well as AMPH-induced locomotor activity. Ex-4 did not induce behavioral responses reflecting anxiety or aversion. Our findings implicate GLP-1R signaling as a novel modulator of psychostimulant-induced behavior and therefore a potential therapeutic target for psychostimulant abuse.

Verbatim abstract via PubMed 22465309 ↗